At nine months.

These outcomes were presented during the Cardiovascular Analysis Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. ‘I am impressed with how constant the BVS data have been to date, as the nine-month data are compelling and supportive of previously positive results,’ said John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand, and co-principal investigator for the ABSORB trial. ‘In addition to the positive basic safety data we’ve seen to date, the late loss rate of 0.19 millimeters reported at half a year is comparable to a metallic drug eluting stent, and may address a limitation of metal stents by not leaving metal in the artery.Kaiser Family Foundation. Copyright 2009 Advisory Board Kaiser and Company Family members Foundation. All rights reserved.

AACR’s 6th Annual Landon Awards recognize Richard Kolodner, Douglas Lowy and John Schiller Scientists whose discoveries have got led to fundamental developments in the technology and treatment of cancer are the recipients of two prestigious international prizes offered by the Kirk A. And Dorothy P. Landon Basis and the American Association for Cancer Research. The Kirk A. Landon-AACR Prize for Simple Cancer Dorothy and Analysis P. Landon-AACR Prize for Translational Cancers Research are the largest such awards wanted to cancer researchers from a professional culture of their peers. The recipients for each prize receive an unrestricted money award of $200,000 and present a scientific lecture at the AACR Annual Getting together with, held this year from April 14-18 in LA, California.